Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary : the first two cases
INTRODUCTION: At present, neither specific curative treatment nor vaccines for novel coronavirus 2019 (COVID-19) are available. There is an urgent need to look for alternative strategies for COVID-19 treatment especially in the case of severe and/or critically ill patients with cytokine release syndrome (CRS).
AIM: Convalescent plasma proved to increase survival rates in other severe viral infections. Therefore, convalescent plasma could be a promising treatment option for severe COVID-19 patients.
METHOD: In our article, we present the first two critically ill Hungarian patients with COVID-19 infection treated with convalescent fresh frozen plasma.
RESULTS: At the time of plasma therapy both patients were on mechanical ventilation and received antiviral agents and a full scale of supportive care. Each patient received 3 × 200 mL of convalescent plasma of recently recovered donors with sufficient novel anti-coronavirus IgG titers. Subsequent to convalescent plasma infusion, oxygenization improved and inflammatory markers decreased in both individuals. As compared to pretransfusion, lymphocyte counts increased and interleukin-6 level lessened. Both patients were weaned from mechanical ventilation within 2 weeks of treatment. No severe adverse effects were observed.
CONCLUSIONS: Our experience indicates that convalescent plasma therapy is well tolerated and could potentially improve clinical outcomes. Optimal dose and timing as well as precise assessment of clinical benefit of convalescent plasma therapy will need further investigation in larger, well-controlled trials. This is the first report of the successful use of convalescent plasma in the treatment of critically ill patients with COVID-19 infection in Hungary. Orv Hetil. 2020; 161(27): 1111-1121.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 161(2020), 27 vom: 01. Juli, Seite 1111-1121 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Az első két sikeres, convalescens friss fagyasztott plazmával történő terápia hazai alkalmazása intenzív osztályon kezelt, kritikus állapotú, COVID–19-fertőzésben szenvedő betegekben: (A COVID–19-pandémia orvosszakmai kérdései) |
|---|
| Beteiligte Personen: |
Bobek, Ilona [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID–19 |
|---|
| Anmerkungen: |
Date Completed 23.06.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2020.31901 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311426379 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311426379 | ||
| 003 | DE-627 | ||
| 005 | 20231225142230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2020.31901 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311426379 | ||
| 035 | |a (NLM)32564002 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Bobek, Ilona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary |b the first two cases |
| 246 | 3 | 3 | |a Az első két sikeres, convalescens friss fagyasztott plazmával történő terápia hazai alkalmazása intenzív osztályon kezelt, kritikus állapotú, COVID–19-fertőzésben szenvedő betegekben: (A COVID–19-pandémia orvosszakmai kérdései) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: At present, neither specific curative treatment nor vaccines for novel coronavirus 2019 (COVID-19) are available. There is an urgent need to look for alternative strategies for COVID-19 treatment especially in the case of severe and/or critically ill patients with cytokine release syndrome (CRS) | ||
| 520 | |a AIM: Convalescent plasma proved to increase survival rates in other severe viral infections. Therefore, convalescent plasma could be a promising treatment option for severe COVID-19 patients | ||
| 520 | |a METHOD: In our article, we present the first two critically ill Hungarian patients with COVID-19 infection treated with convalescent fresh frozen plasma | ||
| 520 | |a RESULTS: At the time of plasma therapy both patients were on mechanical ventilation and received antiviral agents and a full scale of supportive care. Each patient received 3 × 200 mL of convalescent plasma of recently recovered donors with sufficient novel anti-coronavirus IgG titers. Subsequent to convalescent plasma infusion, oxygenization improved and inflammatory markers decreased in both individuals. As compared to pretransfusion, lymphocyte counts increased and interleukin-6 level lessened. Both patients were weaned from mechanical ventilation within 2 weeks of treatment. No severe adverse effects were observed | ||
| 520 | |a CONCLUSIONS: Our experience indicates that convalescent plasma therapy is well tolerated and could potentially improve clinical outcomes. Optimal dose and timing as well as precise assessment of clinical benefit of convalescent plasma therapy will need further investigation in larger, well-controlled trials. This is the first report of the successful use of convalescent plasma in the treatment of critically ill patients with COVID-19 infection in Hungary. Orv Hetil. 2020; 161(27): 1111-1121 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID–19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a convalescens plazma | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a interleukin-6 | |
| 700 | 1 | |a Gopcsa, László |e verfasserin |4 aut | |
| 700 | 1 | |a Réti, Marienn |e verfasserin |4 aut | |
| 700 | 1 | |a Bekő, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Hancz, Lilla |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, Botond |e verfasserin |4 aut | |
| 700 | 1 | |a Molnár, Eszter |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Sándor |e verfasserin |4 aut | |
| 700 | 1 | |a Reményi, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Sebestyén, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Sinkó, János |e verfasserin |4 aut | |
| 700 | 1 | |a Szlávik, János |e verfasserin |4 aut | |
| 700 | 1 | |a Szolnoky, Miklós |e verfasserin |4 aut | |
| 700 | 1 | |a Vályi-Nagy, István |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 161(2020), 27 vom: 01. Juli, Seite 1111-1121 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:2020 |g number:27 |g day:01 |g month:07 |g pages:1111-1121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2020.31901 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 2020 |e 27 |b 01 |c 07 |h 1111-1121 | ||